Stock of the Day

August 5, 2019

IDEXX Laboratories (IDXX)

$567.44
-$8.63 (-1.5%)
Market Cap: $45.44B

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Bull Case

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • The company reported strong earnings per share (EPS) of $3.47 for the latest quarter, exceeding analyst expectations, which indicates robust financial performance.
  • IDEXX Laboratories, Inc. has a high return on equity of 70.87%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
  • Revenue growth of 14.3% compared to the same quarter last year demonstrates the company's expanding market presence and demand for its diagnostic products and services.
  • The current stock price is around $720, which reflects a favorable valuation in light of the company's strong financial metrics and growth potential.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with several upgrades indicating positive sentiment and potential for future price appreciation.

IDEXX Laboratories Bear Case

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Recent price target reductions by analysts, such as UBS Group lowering their target from $730 to $640, may indicate concerns about the stock's near-term performance.
  • Despite strong earnings, the competitive landscape in the diagnostic products market could pressure margins and growth rates in the future.
  • With a net margin of 24.63%, while healthy, there may be room for improvement, and any decline could impact profitability.
  • Market volatility and economic uncertainties could affect investor sentiment and stock performance, particularly in sectors reliant on discretionary spending.
  • Four analysts have rated the stock as a Hold, suggesting that some investors may be cautious about its growth prospects compared to other investment opportunities.
← Previous Stock of the DayNext Stock of the Day →

Recent News